PIA
RETA

Piedmont Investment Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Piedmont Investment Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-276
Closed -$10K – 2473
2018
Q2 		$10K Buy
+276
New +$8.41K ﹤0.01% 1843

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Piedmont Investment Advisors's RETA Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2018, closing a stake of 276 shares — an estimated $10K sold.

Piedmont Investment Advisors first reported a position in RETA in Q2 2018 and held it in 1 quarter. The position peaked at $10K in Q2 2018. 119 funds tracked by Wall St. Rank hold RETA as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 276 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2018, an estimated $10K.
  • Piedmont Investment Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $10K in Q2 2018.
  • 119 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.